|
|
|
| Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang | In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead eHSC product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants. Listen now! |
|
|
|
|
Teams often do a brilliant job executing during the middle of projects. Once a project has been defined and it gains momentum, the project moves along rapidly, until it is time for final deliverables. Ken Ford offers advice for expediting the beginning and the end of projects. |
|
|
|
|
|
|
|
|
| Handling Substantial Modifications Under The CTR | The transition of ongoing clinical trials to meet CTR requirements can be challenging. Examine some key considerations, including substantial modification processes and strategic dossier updates. |
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
Connect With Life Science Leader: |
|
|
|